Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/38998
Conference/Presentation Title: | Clinical outcomes in patients treated with the fully absorbable, everolimus-eluting renuviatm scaffold: Primary endpoint results from the fast first human use study. | Authors: | Meredith I. ;Allocco D.;Christen T.;El-Jack S.;Stewart J.;Layland J.;Whitbourn R.;Walters D.;Seneviratne S. ;Erglis A. | Institution: | (Seneviratne) Monash Medical Centre, Clayton, VIC, Australia (Erglis) P. Stradins Clinical University Hospital, Riga, Latvia (Walters) Prince Charles Hospital, Chermside, QLD, Australia (Whitbourn) St Vincent's Hospital Melbourne, South Yarra, VIC, Australia (Layland) Peninsula Health, Frankston, VIC, Australia (Stewart) Auckland City Hospital, Auckland, New Zealand (El-Jack) North Shore Hospital, Takapuna, New Zealand (Christen) Boston Scientific Corporation, Marlborough, MA, United States (Allocco) Boston Scientific, Maple Grove, MN, United States (Meredith) Boston Scientific Corporation, Marlboro, MA, United States | Presentation/Conference Date: | 20-Dec-2017 | Copyright year: | 2017 | Publisher: | Elsevier USA | Publication information: | Journal of the American College of Cardiology. Conference: 29th Annual Symposium Transcatheter Cardiovascular Therapeutics, TCT 2017. Denver, CO United States. 70 (18 Supplement 1) (pp B342), 2017. Date of Publication: October 2017. | Abstract: | BACKGROUND Permanent stenting with bare metal or drug-eluting stents in the coronary artery is associated with neoatherosclerosis and late thrombotic events. Completely bioabsorbable drug-eluting scaffolds may potentially reduce the risk of late adverse events. RENUVIATM, a balloon expandable scaffold, is made of bioabsorbable poly(L-lactide) and everolimus-eluting abluminal poly(D, L-lactideco- glycolide) polymers. Compared to currently available bioabsorbable scaffolds, RENUVIATM incorporates an optimized design with thinner struts to improve deliverability and overexpansion capabilities, and scaffold fracture resistance. This study evaluates the safety and performance of RENUVIATM in subjects with de novo coronary lesions. Data through 6 months will be reported for the first time at TCT 2017. METHODS Subjects with single de novo native coronary artery lesion (length: <=12mm; reference vessel diameter:>= 2.75mm and <=3.25mm) were enrolled in this prospective, multi-center, single arm feasibility study (N=33). A single scaffold size (3.0mmx16mm) was available for use in the study. The primary endpoints are clinical procedural success (% diameter stenosis <=30% and no in-hospital MACE [death, MI or TLR]) and 6-month angiographic in-scaffold late loss. RESULTS The mean age of patients was 62 years, 67% were male, 24% had medically-treated diabetes, and >60% were treated for hypertension or hyperlipidemia. At the time of writing, 6-month data were available in 22 patients. Clinical procedural success was 90.9% (30/33) due to 3 peri-procedural non-Q-wave MIs. No deaths, TLR, or scaffold thromboses were observed in the analyzed population. At 6 months, angiographic late loss was 0.28+/-0.25 mm in-scaffold and 0.17+/-0.26 mm in-segment; and % diameter stenosis was 19.45+/-11.14% in-scaffold and 26.11+/-9.77 in-segment. The in-scaffold % net volume obstruction was 5.48+/-4.66% (N=17), as measured by IVUS. CONCLUSION Bioabsorbable scaffold technology represents a promising strategy for treatment of coronary artery disease. Complete 6 month data from the FAST study will be available for presentation at TCT and will provide insight into the safety and performance of the second generation RENUVIATM Fully Absorbable Scaffold. | Conference Start Date: | 2017-10-29 | Conference End Date: | 2017-11-02 | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1016/j.jacc.2017.09.1054 | ISSN: | 1558-3597 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/38998 | Type: | Conference Abstract | Subjects: | female fracture human hyperlipidemia hypertension male middle aged non ST segment elevation myocardial infarction obstruction *outcome assessment prospective study stenosis thrombosis writing *everolimus adult drug therapy feasibility study blood vessel diameter diabetes mellitus death coronary artery disease clinical trial *clinical outcome clinical article writing adult blood vessel diameter clinical article *clinical outcome clinical trial coronary artery disease death diabetes mellitus drug therapy feasibility study female fracture human hyperlipidemia hypertension male middle aged non ST segment elevation myocardial infarction obstruction *outcome assessment prospective study stenosis thrombosis |
Appears in Collections: | Conferences |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.